## CITATION REPORT List of articles citing

Belzutifan: First Approval

DOI: 10.1007/s40265-021-01606-x Drugs, 2021, 81, 1921-1927.

Source: https://exaly.com/paper-pdf/91092663/citation-report.pdf

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #  | Paper   | IF   | Citations |
|----|---|------|-----------|
| 35 | Multi-Omics Profiling to Assess Signaling Changes upon VHL Restoration and Identify Putative VHL Substrates in Clear Cell Renal Cell Carcinoma Cell Lines <i>Cells</i> , <b>2022</b> , 11,                      | 7.9  | 1         |
| 34 | Phase 2 Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor <i>Clinical Cancer Research</i> , <b>2022</b> ,                               | 12.9 | 2         |
| 33 | Genetics of Pheochromocytomas and Paragangliomas Determine the Therapeutical Approach <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,  | 6.3  | 1         |
| 32 | First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?. <i>Drugs</i> , <b>2022</b> , 82, 439   | 12.1 | 0         |
| 31 | [Ga]Ga-PSMA-11 PET/CT has potential application in predicting tumor HIF-2\(\text{Lexpression}\) and therapeutic response to HIF-2\(\text{Lentagonists}\) in patients with RCC European Radiology, <b>2022</b> , | 8    | O         |
| 30 | TET2 suppresses VHL deficiency-driven clear cell renal cell carcinoma by inhibiting HIF signaling <i>Cancer Research</i> , <b>2022</b> ,  | 10.1 | 2         |
| 29 | A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021 <i>Naunyn-Schmiedebergys Archives of Pharmacology</i> , <b>2022</b> , 1   | 3.4  | 1         |
| 28 | Fluorine-containing drugs approved by the FDA in 2021. Chinese Chemical Letters, 2022,  | 8.1  | 4         |
| 27 | Delayed onset anterior uveitis and macular edema after cessation of pembrolizumab. <i>American Journal of Ophthalmology Case Reports</i> , <b>2022</b> , 101631   | 1.3  | O         |
| 26 | Hypoxia signaling in human health and diseases: implications and prospects for therapeutics. <i>Signal Transduction and Targeted Therapy</i> , <b>2022</b> , 7,   | 21   | 4         |
| 25 | Noncoding RNAs as sensors of tumor microenvironmental stress. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2022</b> , 41,   | 12.8 | O         |
| 24 | First clinical experience with belzutifan in von Hippellindau diseaselassociated CNS hemangioblastoma. <i>CNS Oncology</i> , <b>2022</b> , 11,  | 4    |           |
| 23 | Molecular mechanisms underlying the role of hypoxia-inducible factor-1 \( \frac{1}{2} \)n metabolic reprogramming in renal fibrosis. \( \textit{Frontiers in Endocrinology}, 13, \)                             | 5.7  | 1         |
| 22 | HIF in Gastric Cancer: Regulation and Therapeutic Target. <b>2022</b> , 27, 4893  |      |           |
| 21 | Targeted Therapies in Pheochromocytoma and Paraganglioma.   |      | O         |
| 20 | Systemic Therapy for Pancreatic Neuroendocrine Tumors. <b>2022</b> ,  |      | 0         |
| 19 | Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma (Review). <b>2022</b> , 24,  |      | 2         |

| 18 | Genetics of Pancreatic Neuroendocrine Tumors. 2022,   | 1     |
|----|---|-------|
| 17 | Multidisciplinary management of patients diagnosed with von Hippel-Lindau disease: A practical review of the literature for clinicians. <b>2022</b> ,   | O     |
| 16 | The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies. <b>2022</b> , 21,  | 1     |
| 15 | Aumolertinib challenge as an optional treatment in advanced non small-cell lung cancer after osimertinib failure with epidermal growth factor receptor-sensitive mutation: A case series. <b>2022</b> , 24, | O     |
| 14 | Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.   | 0     |
| 13 | Hypoxia Inducible factor 2 alpha (HIF2∄inhibitors: targeting genetically driven tumor hypoxia.  | 1     |
| 12 | Neurological Applications of Belzutifan in von Hippel Lindau Disease.   | 0     |
| 11 | VHL syndrome without clear family history: A rare case report and literature review of Chinese patients. 13,  | 0     |
| 10 | New drug approvals for 2021: Synthesis and clinical applications. <b>2023</b> , 245, 114898   | 0     |
| 9  | Severinia buxifolia-isolated acridones inhibit lung cancer invasion and decrease HIFprotein synthesis involves 5DTR-mediated translation inhibition. <b>2022</b> , 154570                                   | O     |
| 8  | Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics. <b>2023</b> , 88, 46-66   | 1     |
| 7  | Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options. 28, 6827-6845   | 0     |
| 6  | Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors.   | 0     |
| 5  | Multi-level interaction between HIF and AHR transcriptional pathways in kidney carcinoma. <b>2023</b> , 6, e20220   | 01756 |
| 4  | Inflammatory Networks in Renal Cell Carcinoma. <b>2023</b> , 15, 2212   | 0     |
| 3  | Targeting angiogenesis in oncology, ophthalmology and beyond.   | O     |
| 2  | Fluorine-a small magic bullet atom in the drug development: perspective to FDA approved and COVID-19 recommended drugs.   | 0     |
| 1  | Drug discovery and repositioning for glioblastoma multiforme and low-grade astrocytic tumors. <b>2023</b> , 147-200   | O     |